Landos Biopharma Inc - Company Profile
Powered by 
All the data and insights you need on Landos Biopharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Landos Biopharma Inc Strategy Report
- Understand Landos Biopharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Landos Biopharma Inc (Landos) is a biopharmaceutical company. It develops oral therapeutics for the treatment of autoimmune diseases. The company pipeline product includes LANCL2, NLRX1, PLXDC2BT-11 small molecule therapeutics for the treatment of anti-inflammatory disease. It utilizes lanthionine synthetase C-Like 2 (LANCL2) technology for developing their products. The company also includes development of BT-11 and NX-13 for the treatment of UC and CD. The company serves in the therapeutic areas of inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Landos is headquartered in Blacksburg, Virginia, the US.
Headquarters
United States of America
Address
1800 Kraft Drive, Suite 216, Blacksburg, Virginia, 24060
Website
www.landosbiopharma.com
Telephone
1 540 8182844
No of Employees
19
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LABP (NASD)
EPS
XYZ
Net Income (2022)
XYZ
44.2%
(2022 vs 2021)
Market Cap*
$69.6M
Net Profit Margin (2020)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Landos Biopharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| LANCL2: |
| BT-11 |
| NLRX1 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with KU Leuven and University Hospitals Leuven to better understand the effects of NX-13 on cells of the epithelium. |
| 2021 | Contracts/Agreements | In September, the company and the Icahn School of Medicine entered into a research collaboration to conduct a Phase 2 trial of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, to treat patient with moderate-to-severe Crohn’s disease. |
| 2021 | Contracts/Agreements | In August, the company entered into a research collaboration with Johns Hopkins University School of Medicine to focus on validating the NLRX1 immunometabolic pathway in multiple Sclerosis. |
Competitor Comparison
| Key Parameters | Landos Biopharma Inc | Equillium Inc | 9 Meters Biopharma Inc | Bridge Pharma Inc | Metacrine Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Blacksburg | La Jolla | Raleigh | Sarasota | San Diego |
| State/Province | Virginia | California | North Carolina | Florida | California |
| No. of Employees | 19 | 45 | 10 | - | 32 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chris Garabedian | Chairman | Executive Board | 2021 | 56 |
| Gregory Oakes | President; Director; Chief Executive Officer | Executive Board | 2022 | 55 |
| Fabio Cataldi | Executive Vice President; Chief Medical Officer | Senior Management | 2022 | 56 |
| Patrick Truesdell | Vice President - Controller and Principal Accounting Officer | Senior Management | - | - |
| David Pereira | Vice President - CMC | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer